Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma-Reference-Cited by-同舟云学术

Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma

Published:2019-02 Issue:1 Volume:29 Page:85-88
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Seremet Teofila,Planken Simon,Schwarze Julia K.,Jansen Yanina,Vandeweerd Laura,van den Begin Robbe,Tsechelidis Ioannis,Lienard Danielle,Del Marmol Véronique,Neyns Bart

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference19 articles.

1. Ipilimumab: controversies in its development, utility and autoimmune adverse events;Weber;Cancer Immunol Immunother,2009

2. Immune checkpoint blockade in cancer therapy;Postow;J Clin Oncol,2015

3. PD-1 and PD-L1 antibodies in cancer: current status and future directions;Balar;Cancer Immunol Immunother,2017

4. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

5. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor;Hu;Clin Cancer Res,2006

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec;JAAD Case Reports;2024-01

2. Immunomodulatory effect of locoregional therapy in the tumor microenvironment;Molecular Therapy;2023-04

3. Intratumoral administration of CD1c (BDCA-1)⁺ and CD141 (BDCA-3)⁺ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial;Journal for ImmunoTherapy of Cancer;2022-09

4. Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity;Expert Opinion on Drug Safety;2021-12-27

5. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience;Annals of Surgical Oncology;2021-10-14